American Society of Hematology

Figure 1.

$Figure 1. Study design and flowchart of the analyses. Initially proteins in all samples were separated using 2D-PAGE. PTCL-NOS cases were dichotomized according to PCA and clinical outcome in C1 vs C2 and G1 vs G2, respectively. Differential protein expressions were compared in: analysis A, PTCL-NOS (n = 18) vs N (n = 8); analysis B, PCA defined clusters C1 (n = 7) vs C2 (n = 11); and analysis C, PTCL-NOS patients with primary refractory disease (G1) with survival <100 days (n = 4) vs PTCL-NOS patients with chemosensitive disease and survival >2 years (G2) (n = 8). In the latter analysis, 6 cases were omitted for failing to fulfill the defined criteria of treatment response. Spots with ≥twofold differential expression were excised, and protein identifications were performed by liquid chromatography tandem mass spectrometry (LC-MS/MS). ENO1, TPI1, and ALDH2 protein expression was assessed in a larger cohort of PTCL-NOS patients (n = 87) by IHC and digitally quantified using digital image analysis on TMA cores. ALDH2, aldehyde dehydrogenase 2, mitochondrial; CR, complete remission; N, nonneoplastic tissue; TPI1, triosephosphate isomerase.$

Study design and flowchart of the analyses. Initially proteins in all samples were separated using 2D-PAGE. PTCL-NOS cases were dichotomized according to PCA and clinical outcome in C1 vs C2 and G1 vs G2, respectively. Differential protein expressions were compared in: analysis A, PTCL-NOS (n = 18) vs N (n = 8); analysis B, PCA defined clusters C1 (n = 7) vs C2 (n = 11); and analysis C, PTCL-NOS patients with primary refractory disease (G1) with survival <100 days (n = 4) vs PTCL-NOS patients with chemosensitive disease and survival >2 years (G2) (n = 8). In the latter analysis, 6 cases were omitted for failing to fulfill the defined criteria of treatment response. Spots with ≥twofold differential expression were excised, and protein identifications were performed by liquid chromatography tandem mass spectrometry (LC-MS/MS). ENO1, TPI1, and ALDH2 protein expression was assessed in a larger cohort of PTCL-NOS patients (n = 87) by IHC and digitally quantified using digital image analysis on TMA cores. ALDH2, aldehyde dehydrogenase 2, mitochondrial; CR, complete remission; N, nonneoplastic tissue; TPI1, triosephosphate isomerase.

This Feature Is Available To Subscribers Only